N Engl J Med
Kidney Week 2025: Novel drug delivers robust proteinuria reduction in IgA nephropathy
Presented at Kidney Week 2025, this prespecified interim analysis demonstrated that treatment with atacicept resulted in a significantly greater reduction in proteinuria than placebo at week 36 in patients with IgA nephropathy.
Study design: The ongoing, multicenter, double-blind, randomized, placebo-controlled ORIGIN 3 trial (NCT04716231) enrolled 203 patients with IgA nephropathy, assigning them 1:1 to atacicept 150 mg SC once weekly or placebo. Primary endpoint was percentage change in 24-hour urinary protein-to-creatinine ratio at week 36. Safety was rigorously monitored.
Results: At week 36, atacicept achieved a 45.7% reduction in proteinuria vs. 6.8% with placebo (95% confidence interval, 28.9–52.3; P<0.001). Adverse events occurred in 59.3% of atacicept-treated patients and 50.0% of placebo, mostly of mild or moderate severity.
Source:
Lafayette R, et al; ORIGIN Phase 3 Trial Investigators. (2025, November 6). N Engl J Med. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. https://pubmed.ncbi.nlm.nih.gov/41196369/